Application 076806
- Type
- ANDA
- Sponsor
- DR REDDYS
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DEFEROXAMINE MESYLATE | DEFEROXAMINE MESYLATE | INJECTABLE;INJECTION | 500MG/VIAL | No | No |
| 002 | DEFEROXAMINE MESYLATE | DEFEROXAMINE MESYLATE | INJECTABLE;INJECTION | 2GM/VIAL | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A076806-001 | DEFEROXAMINE MESYLATE | DEFEROXAMINE MESYLATE | 500MG/VIAL | INJECTABLE / INJECTION | 2006-03-31 | ||
| A076806-002 | DEFEROXAMINE MESYLATE | DEFEROXAMINE MESYLATE | 2GM/VIAL | INJECTABLE / INJECTION | 2006-03-31 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-10-28 04:53 UTC | 2022-10 | A076806-001 | DEFEROXAMINE MESYLATE | 500MG/VIAL | INJECTABLE / INJECTION | 2006-03-31 | f41ea6bd6efb… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A076806-002 | DEFEROXAMINE MESYLATE | 2GM/VIAL | INJECTABLE / INJECTION | 2006-03-31 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A076806-001 | DEFEROXAMINE MESYLATE | 500MG/VIAL | INJECTABLE / INJECTION | 2006-03-31 | e64feba35796… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A076806-002 | DEFEROXAMINE MESYLATE | 2GM/VIAL | INJECTABLE / INJECTION | 2006-03-31 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A076806-001 | DEFEROXAMINE MESYLATE | 500MG/VIAL | INJECTABLE / INJECTION | 2006-03-31 | cb3db0bc1861… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A076806-002 | DEFEROXAMINE MESYLATE | 2GM/VIAL | INJECTABLE / INJECTION | 2006-03-31 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A076806-001 | DEFEROXAMINE MESYLATE | 500MG/VIAL | INJECTABLE / INJECTION | 2006-03-31 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A076806-002 | DEFEROXAMINE MESYLATE | 2GM/VIAL | INJECTABLE / INJECTION | 2006-03-31 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Deferoxamine | DEFEROXAMINE MESYLATE | Fresenius Kabi USA, LLC | d91e16df-8daa-4cd2-86a2-273eaa2446e0 | 2026-06-15 | Warnings, Adverse reactions | DEFEROXAMINE MESYLATE |
| Deferoxamine mesylate | DEFEROXAMINE MESYLATE | Apotex Corp. | c99553fb-3fae-b88a-6c2c-efa7520197f9 | 2026-05-29 | Warnings, Adverse reactions | Deferoxamine mesylate DEFEROXAMINE MESYLATE |
| Deferoxamine Mesylate | DEFEROXAMINE MESYLATE | Hospira, Inc. | f9ab6b1c-98d0-4373-0e9b-b10cb4a67543 | 2026-04-06 | Warnings, Adverse reactions | Deferoxamine Mesylate DEFEROXAMINE MESYLATE |
| Deferoxamine mesylate | DEFEROXAMINE MESYLATE | Gland Pharma Limited | 598fba68-f46e-4b6e-894c-63c2940b2063 | 2026-03-06 | Warnings, Adverse reactions | Deferoxamine mesylate DEFEROXAMINE MESYLATE |
| Desferal | DEFEROXAMINE MESYLATE | MITEM PHARMA | 38eff751-96c5-c48a-e063-6294a90a0e48 | 2025-07-02 | DEFEROXAMINE MESYLATE | |
| Desferal | DEFEROXAMINE MESYLATE | Novartis Pharmaceuticals Corporation | a7174843-5965-49fc-b842-f7eff7b48bbc | 2025-06-17 | Warnings, Adverse reactions | DEFEROXAMINE MESYLATE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.